Table 1 Demographic, biochemical, serological characteristics, treatment preferences and outcomes of 390 graves’ disease patients
Patient’s characteristics | Number (Percent) |
|---|---|
Sex | |
Females | 296 (75.9%) |
Males | 94 (24.1%) |
Family history of thyroid disease | 234 (60%) |
Thyroid function at presentation | 344 (88.2%) |
T3-Toxicosis | 10 (2.9%) |
Subclinical hyperthyroidism | 11 (3.2%) |
Overt hyperthyroidism | 323 (93.9%) |
mOH – mild overt hyperthyroidism | 144 (44.6%) |
MOH – moderate overt hyperthyroidism | 118 (36.5%) |
SOH – severe overt hyperthyroidism | 61 (18.9%) |
TSH receptor autoantibodies | |
Order rate | 340 (87.2%) |
Positivity rate | 330 (97.1%) |
Thyro-peroxidase autoantibodies | |
Order rate | 226 (57.9%) |
Positivity rate | 169 (74.8%) |
Thyroglobulin autoantibodies | |
Order rate | 119 (30.5%) |
Positivity rate | 65 (54.6%) |
Thyroid eye disease | 69 (17.7%) |
Goiter | 284 (72.8%) |
Treatment modality | |
Medical treatment (ATD’s) | 351 (90%) |
Surgery | 21 (5.4%) |
Radioiodine ablation | 17 (4.3%) |
Medical treatment outcomes | |
Remission | 62 (17.7%) |
Relapse | 18 (29%) |
Hypothyroidism | 10 (2.85%) |